Novartis

Plavix copycat pops up in Europe

admin — Fri, 09 May 2008 06:59:58 -0400

Call it generic Whac-a-Mole. Sanofi-Aventis and Bristol-Myers Squibb have bludgeoned copycat Plavix in the U.S., but competition is now popping up in Europe. Swiss drugmaker Schweizerhall Holding Read more...

BMS: Buyer or buyout target?

admin — Wed, 07 May 2008 06:59:58 -0400

Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...

Profits rise at Novartis, Merck, Lilly

admin — Mon, 21 Apr 2008 06:59:58 -0400

Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from Read more...

Falling dollar, falling drugmaker prices

admin — Tue, 15 Apr 2008 06:59:57 -0400

Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...

Vasella touts Novartis' diversification

admin — Mon, 14 Apr 2008 06:59:55 -0400

Novartis CEO Daniel Vasella (photo) talked up his company's prospects in an interview with the Swiss weekly Sonntag, Read more...

Novartis taps new U.S. pharma chief

admin — Fri, 11 Apr 2008 06:59:58 -0400

The musical chairs game in Novartis' top management ranks is continuing as new pharma chief Joe Jimenez revamps the ranks. The Swiss drugmaker has appointed Ludwig Hantson to top its U.S. Read more...

FDA probes Roche, Novartis meds

admin — Fri, 11 Apr 2008 06:59:56 -0400

The transplant drug probe is widening. FDA says it's identified 16 cases of an often-fatal neurological disease among patients taking Roche's CellCept drug, used to prevent organ rejection. The Read more...

Pros use pills to boost brainpower

admin — Thu, 10 Apr 2008 06:59:57 -0400

Fuzzy-headed today? Then pop a pill. Professionals of all kinds are doing it these days, according to a survey taken by Nature. Read more...

What did Vasella see in Alcon?

admin — Wed, 09 Apr 2008 06:59:55 -0400

Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 Read more...

SPOTLIGHT: Novartis: No more deals, no Roche sale

admin — Tue, 08 Apr 2008 06:59:52 -0400

Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for Read more...